HTA and coverage decision-making processes: The key to facilitating transparent access to medicines
28-29th September 2011, Surrey, UK
This workshop addressed the central question: given the diversity in the processes of HTA evaluation, coverage decision making and reimbursement between countries, how can the activities of such different systems be compared?
Workshop objectives
- Determine if different HTA and coverage systems are comparable
- For comparisons to be valid, it is important to know on what basis they are made and to understand that the HTA and coverage bodies operate within very different frameworks.
- Can a systematic approach to mapping the processes from regulatory approval to reimbursement provide an understanding of where each process fits into the organisations and healthcare systems, the nature of the organisations and hence the meaningfulness of cross comparisons?
- Ascertain if there is value in developing HTA-related industry benchmarking.
- Companies routinely use internal targets to drive performance, but can comparison between companies in terms of the inclusion of HTA requirements into clinical development and the outcome on the following rollout be used to provide an understanding of the influence of HTA on development plans and rollout?
- Can such benchmarking provide insight into predictability of time or success across jurisdictions?
- Establish whether there is value in developing performance indicators for HTA and coverage bodies
- Such indicators could be used for the purpose of measuring ongoing reforms and change, identifying existing procedural facilitators and obstacles and for learning by comparison with peer agencies.
- Is it possible to develop an international set of performance indicators, or should such comparisons be best conducted by region or by similarity of organisation?